MRSA: Mechanism of resistance, epidemiology, risk factors, prophylaxis, therapy;MRSA: Resistenzmechanismen, epidemiologie, risikofaktoren, prophylaxe, therapie

Zeitschrift fur Herz-, Thorax- und Gefasschirurgie

Volumn 19, Issue 2, 2005, Pages 78-88

  Heizmann, P ^a   Heizmann, W R ^b   Hetzer, R ^a  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^b Zentrum für Mikrobiologie und Infektiologie   (Germany)

Author keywords

Epidemiology; MRSA; Prophylaxis; Risk factors; Therapy

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFSULODIN; CEFTAZIDIME; CEPHALOSPORIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DICLOXACILLIN; FLUCLOXACILLIN; FOSFOMYCIN; IMIPENEM; LEVOFLOXACIN; LINCOSAMIDE; LINEZOLID; MACROLIDE; METICILLIN; MIKAMYCIN B; OCTENIDINE; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; PENICILLIN G; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOGRAMIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM CULTURE; COMMUNITY; EPIDEMIOLOGICAL DATA; HEALTH CARE SYSTEM; HEALTH CENTER; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; NONHUMAN; PRACTICE GUIDELINE; PROPHYLAXIS; REVIEW; RISK FACTOR; STAPHYLOCOCCUS INFECTION;

EID: 18744369056     PISSN: 09309225     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00398-005-0486-0     Document Type: Review

References (58)

1. Beaujean DJ, Weersink AJ, Blok HE, Frenay HM, Verhoef J (1999) Determining risk factors for methicillin-resistant Staphylococcus aureus carriage after discharge from hospital. J Hosp Infect 42(3):213-218
2. Berger-Bächi B, Strassle A, Kayser FH (1989) Natural methicillin resistance in comparison with that selected by in vitro drug exposure in Staphylococcus aureus. J Antimicrob Chemother 23(2):179-188
3. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ (2003) Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 36(2):159-168
4. Borer A, Gilad J, Yagupsky P, Peled N, Porat N, Trefler R, Shprecher-Levy H, Riesenberg K, Shipman M, Schlaeffer F (2002) Community-acquired methicillin-resistant Staphylococcus aureus in institutionalized adults with developmental disabilities. Emerg Infect Dis 8:966-970
5. Boyce JM (1997) Epidemiology and prevention of nosocomial Infections. In: Crossley KB, Archer GL (eds) The Staphylococci in human disease. Churchill Livingstone New York, Edinburgh, London, Madrid, Melbourne, San Fransisco, Tokyo
6. Buckingham SC, McDougal LK, Cathey LD, Comeaux K, Craig AS, Fridkin SK, Tenover FC (2004) Emergence of community-associated methicillin-resistant Staphylococcus aureus at a Memphis, Tennessee Children's Hospital. Pediatr Infect Dis J 23:619-624
7. Chambers HF (2001) The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 7:178-182
8. Chang SC, Hsieh SM, Chen ML, Sheng WH, Chen YC (2000) Oral fusidic acid fails to eradicate methicillin-resistant Staphylococcus aureus colonization and results in emergence of fusidic acid-resistant strains. Diagn Microbiol Infect Dis 36:131-136
9. Carleton HA, Diep BA, Charlebois ED, Sensabaugh GF, Perdreau-Remington F (2004) Community-adapted methicillin-resistant Staphylococcus aureus (MRSA): population dynamics of an expanding community reservoir of MRSA. J Infect Dis, 190:1730-1738
10. Cooper BS, Stone SP, Kibbler CC, Cookson BD, Roberts JA, Medley GF, Duckworth G, Lai R, Ebrahim S (2004). BMJ 329:533-540
11. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y (2003) Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36(1):53-59
12. Couto I, Wu SW, Tomasz A, de Lencastre H (2003) Development of Methicillin Resistance in Clinical Isolates of Staphylococcus sciuri by Transcriptional Activation of the mecA Homologue Native to the Species J Bacteriol 185:645-653
13. Crowcroft NS, Ronveaux O, Monnet DL, Mertens R (1999) Methicillin-resistant Staphylococcus aureus and antimicrobial use in Belgian hospitals. Infect Control Hosp Epidemiol (1):31-36
14. Cruciani M, Gatti G, Lazzarini L, Furlan G, Broccali G, Malena M, Franchini C, Concia E (1996) Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 38:865-869
15. Davis KA, Stewart JJ, Crouch HK, Florenz CE, Hospenthal DR (2004) Clin Infect Dis 39:776-782
16. Dupeyron C, Campillo B, Bordes M, Faubert E, Richardet JP, Mangeney N (2002) A clinical trial of mupirocin in the eradication of methicillin-resistant Staphylococcus aureus nasal carriage in a digestive disease unit. J Hosp Infect 52(4):281-287
17. Ellis MW, Hospenthal DR, Dooley DP, Gray PJ, Murray CK (2004) Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin Infect Dis 39:971-979
18. Fey PD, Said-Salim B, Rupp ME, Hinrichs SH, Boxrud DJ, Davis CC, Kreiswirth BN, Schlievert PM (2003) Comparative molecular analysis of community- or hospital-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 47:196-203
19. Gang RK, Sanyal SC, Mokaddas E, Lari AR (1999) Rifampicin as an adjunct to vancomycin therapy in MRSA septicaemia in burns. Burns 25:640-644
20. Garrouste-Oregas M, Timsit JF, Kallel H, Ben Ali A, Dumay MF, Paoli B et al (2001) Colonization with methicillin-resistant Staphylococcus aureus in ICU patients: morbidity, mortality, and glycopeptide use. Infect Control Hosp Epidemiol 22:687-692
21. Gillet Y, Issartel B, Vanhems P, Fournet JC, Lina G, Bes M, Vandenesch F, Piemont Y, Brousse N, Floret D, Etienne J (2002) Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 359:753-759
22. Girou E, Azar J, Wolkenstein P, Cizeau F, Brun-Buisson C, Roujeau JC (2000) Comparison of systematic versus selective screening for methicillin-resistant Staphylococcus aureus carriage in a high-risk dermatology ward. Infect Control Hosp Epidemiol 21(9):583-587
23. Gould IM, Macckenzie FM, Lopez-Lozano JM, Monnet DL, Wilson R, Beyaert A (2002) Temporal Relationship between Prevalence of Methicillin-Resistant Staphylococcus aureus (MRSA) in One Hospital and Prevalence of MRSA in the Surrounding Community: A Time Series Analysis. 42nd ICAAC Abstracts, American Society for Microbiology, September 27-30, San Diego, CA, p 304
24. Glück U, Gebbers JO (2000) The nose as bacterial reservoir: important differences between the vestibule and cavity. Laryngoscope 110:426-428
25. Graffunder EM, Venezia RA (2002) Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother, 49:999-1005
26. Groom AV, Wolsey DH, Naimi TS, Smith K, Johnson S, Boxrud D, Moore KA, Cheek JE (2001) Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA 286:1201-1205
27. Hanssen A-M, Kjeldsen G, Sollid JUE (2004) Local variants of staphylococcal cassette chromosome mec in sporadic methicillin-resistent Staphylococcus aureus and methicillin-resistant coagulase-negative staphylococci: Evidence of horizontal gene transfer? Antimicrob Agents Chemother 48:285-296
28. Jarløv JO, Høiby N (1998) Coagulase-negative staphylococci in a major Danish university hospital: diversity in antibiotic susceptibility between wards. APMIS 106:411-416
29. Jevons MP (1961) "Celbenin-resistant" staphylococci. BMJ 1:124-125
30. Kang SL, Ryback MJ (1995) Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model. Antimicrob Agents Chemother 39:1505-1511
31. Kerttula AM, Lyytikainen O, Salmenlinna S, Vuopio-Varkila J (2004) Changing epidemiology of methicillin-resistant Staphylococcus aureus in Finland. J Hosp Infect 58:109-114
32. Landman D, Chockalingam M, Quale JM (1999) Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary. Clin Infect Dis 28:1062-1066
33. Löwdin E, Odenholt I, Cars O (1998) In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 42:2739-2744
34. Maraha B, van Halteren J, Verzijl JM, Wintermans RG, Buiting AG (2002) Decolonization of methicillin-resistant Staphylococcus aureus using oral vancomycin and topical mupirocin. Clin Microbiol Infect 8:671-675
35. Markowitz N, Quinn EL, Saravolatz LD (1992) Trimethoprim-sulfamethoxazole compared with Vancomycin for the treatment of Staphylococcus infection. Ann Intern Med 117:390-398
36. Mehall JR, Kite CA, Gilliam CH, Jackson RJ, Smith SD (2002) Enteral feeding tubes are a reservoir for nosocomial antibiotic-resistant pathogens. J Pediatr Surg 37:1011-1012
37. Moise PA, Forrest A, Birmingham MC, Schentag JJ (2002) The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother 50:1017-1026
38. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ (2004) Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 43:925-942
39. Monnet DL, MacKenzie FM, Lopez-Lozano JM, Beyaert A, Camacho M, Wilson R, Stuart D, Gould IM (2004) Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996-2000. Emerg Infect Dis 10:1432-1441
40. NN (2002) Staphylococcus aureus resistant to vancomycin - United States. MMWR 51:565-567
41. Pfeil E, Gustafsson I, Cars O, Wiedemann B (2000) Pharmacology of Quinupristin-Dalfopristin (Q-D) with MSSA and MRSA in Comparison to Vancomycin (VAN). Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, p 36
42. Pujol M, Pena C, Pallares R, Ariza J, Ayats J, Dominguez MA, Gudiol F (1996) Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. Am J Med 100:509-516
43. Roghmann MC, Siddiqui A, Plaisance K, Standiford H (2001) MRSA colonization and the risk of MRSA bacteraemia in hospitalized patients with chronic ulcers. J Hosp Infect 47:98-103
44. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos GM (2004) Relationship of MIC and bactericidal activity to efficacy of Vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42:2398-2402
45. Schmilz F-J, Petridou J, Fluit AC, Hadding U, Peters G, von Eiff C (2000) Distribution of macrolide-resistance genes in Staphylococcus aureus blood-culture isolates from fifteen German university hospitals. M.A.R.S. Study Group. Multicentre Study on Antibiotic Resistance in Staphylococci. Eur J Clin Microbiol Infect Dis 19:385-387
46. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, Yeoh H, Law D, Robbins JB, Schneerson R, Muenz L, Fuller S, Johnson J, Fireman B, Alcorn H, Naso R (2002) Use of a Staphylococcus aureus conjugate vaccine in patients receiving nemodialysis. N Engl J Med 346:491-496
47. Silvestri L, Milanese M, Oblach L, Fontana F, Gregori D, Guerra R, van Saene HK (2002) Enteral vancomycin to control methicillin-resistant Staphylococcus aureus outbreak in mechanically ventilated patients. Am J Infect Control 30:391-399
48. Sloot N, Siebert J, Hoffler U (1999) Eradication of MRSA from carriers by means of whole-body washing with an antiseptic in combination with mupirocin nasal ointment. Zentralbl Hyg Umweltmed 202:513-523
49. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B (2002) Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 34:1481-1490
50. Talon DR, Bertrand X (2001) Methicillin-resistant Staphylococcus aureus in geriatric patients: usefulness of screening in a chronic-care setting. Infect Control Hosp Epidemiol 22:505-509
51. Viale P, Pagani L, Cristini F, Stefini R, Bergomi R, Colombini P, Carosi G (2002) Linezolid for the treatment of central nervous system infections in neurosurgical patients. Scand J Infect Dis 34:456-459
52. Villani P, Regazzi MB, Marubbi F, Viale P, Pagani L, Cristini F, Cadeo B, Carosi G, Bergomi R (2002) Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections. Antimicrob Agents Chemother 46:936-937
53. von Eiff C, Becker K, Machka K, Stammer H, Peters G (2001) Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 344:11-16
54. Vriens M, Blok H, Fluit A, Troelstra A, Van Der Werken C, Verhoef J (2002) Costs Associated with a Strict Policy to Eradicate Methicillin-Resistant Staphylococcus aureus in a Dutch University Medical Center: A 10-Year Survey. Eur J Clin Microbiol Infect Dis 21:782-786
55. Wannet WJ, Spalburg E, Heck ME, Pluister GN, Willems RJ, De Neeling AJ (2004) Widespread dissemination in The Netherlands of the epidemic berlin methicillin-resistant Staphylococcus aureus clone with low-level resistance to oxacillin. J Clin Microbiol 42:3077-3082
56. Washio M, Kiyohara C, Arai Y, Aoyagi K, Okada K, Fujishima M, Maeda M, Ito Y (1998) Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa isolation from pharyngeal swab cultures among the Japanese elderly at admission to a geriatric hospital. Public Health 112:415-417
57. Willke RJ, Glick HA, Li JZ, Kittenhouse BE (2002) Effects of linezolid on hospital length of stay compared with vancomycin in treatment of methicillin-resistant Staphylococcus infections. An application of multivariate survival analysis. Int J Technol Assess Health Care 18:540-554
58. Young DM, Harris HW, Charlebois ED, Chambers H, Campbell A, Perdreau-Remington F, Lee C, Mankani M, Mackersie R, Schecter WP (2004) An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients. Arch Surg 139:947-951